Patient population
active malignant tumour
RECURRENCE, PROSTATE ADENOCARCINOMA
Patients were enrolled between the 1Inclusion criteria were: male, age ≥ 18 years, histopathological proven prostate adenocarcinoma, first suspected recurrence of PCa based on rising PSA after initial curative therapy like radical prostatectomy (RP), with PSA ≥ 0.2 ng/mL confirmed by a subsequent PSA determination, or radiation therapy (RT) with PSA ≥ 2 ng/mL above the nadir after therapy, regardless of the serum concentration of the PSA nadir.Exclusion criteria were: ECOG status > 2; history of previous salvage therapies (including salvage radiotherapy or salvage lymph node dissection), adjuvant radiotherapy, cryotherapy or high-intensity focused ultrasound (HIFU); other active malignant tumour; treatment with: androgen deprivation therapy (ADT) in the past 30 days/ ongoing; colchicine in the past 8 days/ ongoing or hematopoietic colony stimulating factors (CSF) in the past 5 days/ ongoing.